NeuBase Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.17
- Today's High:
- $1.35
- Open Price:
- $1.34
- 52W Low:
- $0.605
- 52W High:
- $12.348
- Prev. Close:
- $1.31
- Volume:
- 696757
Company Statistics
- Market Cap.:
- $2.92 million
- Book Value:
- 5.988
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -43.03%
- Return on Equity TTM:
- -93.46%
Company Profile
NeuBase Therapeutics Inc had its IPO on 2007-05-01 under the ticker symbol NBSE.
The company operates in the Healthcare sector and Biotechnology industry. NeuBase Therapeutics Inc has a staff strength of 37 employees.
Stock update
Shares of NeuBase Therapeutics Inc opened at $1.34 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.17 - $1.35, and closed at $1.29.
This is a -1.53% slip from the previous day's closing price.
A total volume of 696,757 shares were traded at the close of the day’s session.
In the last one week, shares of NeuBase Therapeutics Inc have increased by +37.54%.
NeuBase Therapeutics Inc's Key Ratios
NeuBase Therapeutics Inc has a market cap of $2.92 million, indicating a price to book ratio of 0.2238 and a price to sales ratio of 0.
In the last 12-months NeuBase Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-23408468. The EBITDA ratio measures NeuBase Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, NeuBase Therapeutics Inc’s operating margin was 0% while its return on assets stood at -43.03% with a return of equity of -93.46%.
In Q2, NeuBase Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
NeuBase Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-17.98 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NeuBase Therapeutics Inc’s profitability.
NeuBase Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.524. Its price to sales ratio in the trailing 12-months stood at 0.
NeuBase Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $22.33 million
- Total Liabilities
- $6.12 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
NeuBase Therapeutics Inc ended 2024 with $22.33 million in total assets and $0 in total liabilities. Its intangible assets were valued at $22.33 million while shareholder equity stood at $11.25 million.
NeuBase Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $6.12 million in other current liabilities, 188.00 in common stock, $-114653299.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.75 million and cash and short-term investments were $14.75 million. The company’s total short-term debt was $510,165 while long-term debt stood at $0.
NeuBase Therapeutics Inc’s total current assets stands at $15.52 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0.00 compared to accounts payable of $322131.00 and inventory worth $0.
In 2024, NeuBase Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, NeuBase Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.29
- 52-Week High
- $12.348
- 52-Week Low
- $0.605
- Analyst Target Price
- $140
NeuBase Therapeutics Inc stock is currently trading at $1.29 per share. It touched a 52-week high of $12.348 and a 52-week low of $12.348. Analysts tracking the stock have a 12-month average target price of $140.
Its 50-day moving average was $1.28 and 200-day moving average was $3.32 The short ratio stood at 0.33 indicating a short percent outstanding of 0%.
Around 1215.6% of the company’s stock are held by insiders while 2427.8% are held by institutions.
Frequently Asked Questions About NeuBase Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington’s disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.